Abbott Laboratories $ABT Shares Bought by WealthPlan Investment Management LLC

WealthPlan Investment Management LLC raised its holdings in Abbott Laboratories (NYSE:ABT) by 258.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 23,713 shares of the healthcare product maker’s stock after acquiring an additional 17,102 shares during the quarter. WealthPlan Investment Management LLC’s holdings in Abbott Laboratories were worth $2,971,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Harbor Capital Advisors Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $27,000. Cloud Capital Management LLC acquired a new stake in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $31,000. Bridge Generations Wealth Management LLC acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $33,000. Finally, Copia Wealth Management acquired a new stake in Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, SVP Eric Shroff sold 709 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares in the company, valued at approximately $4,526,575.12. This represents a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of the stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This represents a 0.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock worth $353,097 over the last ninety days. 0.46% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Stifel Nicolaus cut their price objective on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Sanford C. Bernstein cut their price objective on Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Barclays cut their price objective on Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating on the stock in a report on Monday, April 20th. JPMorgan Chase & Co. cut their price objective on Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Finally, Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 29th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.43.

Abbott Laboratories Price Performance

Shares of ABT opened at $84.49 on Friday. The company has a market capitalization of $147.16 billion, a price-to-earnings ratio of 23.67, a P/E/G ratio of 1.41 and a beta of 0.65. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The business’s 50-day moving average is $99.02 and its 200-day moving average is $113.35.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were issued a $0.63 dividend. The ex-dividend date was Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.0%. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.